Arcturus Therapeutics (ARCT) vs Benitec Biopharma (BNTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Benitec Biopharma (BNTC) has outperformed Arcturus Therapeutics (ARCT) over the past year, losing 48.2% versus a loss of 50.0%. Over five years, ARCT leads with a -76.8% price change compared with -86.5% for BNTC. Arcturus Therapeutics is the larger company by market cap ($293.9 million vs $282.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | BNTC |
|---|---|---|
| Share price | $10.34 | $8.11 |
| Market cap | $293.89M | $282.90M |
| 1-day change | -8.25% | -4.14% |
| YTD return | +68.68% | -39.79% |
| 1-year return | -49.95% | -48.18% |
| 5-year return | -76.77% | -86.52% |
| EPS (TTM) | $-3.33 | $-0.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | — |
| Revenue growth (YoY) | -46.14% | — |
| Net income (latest FY) | $-65.78M | $-45.55M |
| Operating margin | -92.96% | — |
| Net margin | -80.19% | — |
| 52-week high | $24.17 | $16.76 |
| 52-week low | $5.50 | $8.06 |
| Distance from 52-week high | -57.22% | -51.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.17% | +200.00% |
| Average volume | 941.87K | 162.32K |
| Shares outstanding | 28.42M | 34.88M |
| Employees | 106 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
ARCT vs BNTC FAQ
Which is bigger, Arcturus Therapeutics or Benitec Biopharma?
Arcturus Therapeutics (ARCT) is larger, with a market capitalization of $293.89M compared with $282.90M for Benitec Biopharma (BNTC).
Which stock has performed better over the past year, ARCT or BNTC?
BNTC returned -48.18% over the past 12 months, compared with -49.95% for ARCT (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Benitec Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.